Ted Fjällman new board member at XNK Therapeutics
XNK Therapeutics AB (“XNK”) today announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors.Ted Fjällman is Partner at Flerie Invest, a European biotech and pharma investor managing a portfolio of more than 25 companies in the US, UK, Sweden, the Netherlands and other countries. Ted has been CEO and board member of several biotech companies engaged in a wide range of areas including immunology, oncology and biologics development and manufacturing. He holds a Ph.D. in Biotechnology and Immunology from the University of Guelph, Canada, and splits his